Pluri Inc. (PLUR): Entry into a Material Definitive Agreement
Pluri Inc. (PLUR) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. ZEO Partnership Agreement On October 26, 2026, Pluri Inc. (“Pluri” or the “Company”) entered into a Partnership Agreement (the “Agreement”) with ZEO ScientifiX, Inc. (“ZEO”) pursuant to which, at the closing of the transaction
- Role
- supplier
- Counterparty
- ZEO ScientifiX, Inc.
- Scope
- exclusive license solely to manufacture and commercialize
Facts are quoted from the filing text and checked against it. Details that could not be matched to the text are left out.
How this was made
The 30-second read
Why it matters
The partnership provides Pluri with a 41% ownership in ZEO, board seats, and royalty rights, potentially enhancing its revenue and valuation.
Market read
The deal is a primary disclosure that could move PLUR stock as investors price in the new equity stake and licensing revenue.
What to watch
Closing conditions and potential change-of-control clauses may delay benefits.
Background
Pluri Inc. filed an 8‑K reporting a material definitive agreement with ZEO ScientifiX, Inc. that includes licensing rights and a substantial equity stake.
Ticker impact
Pluri Inc. entered a partnership agreement granting ZEO a license and receiving a 41% equity stake in ZEO.
likely upside as market prices in the equity stake and licensing upside
Pluri will own 41% of ZEO, obtain board representation and royalty rights, creating significant upside potential.
Market effects
May boost the regenerative medicine sector as partnership highlights commercial licensing trends.
US biotech investors could see increased interest in similar licensing deals.
Limited to niche biotech investors; no broad market effect.
Counterpoint
The deal could dilute Pluri's focus and tie performance to ZEO's execution risk.
Key entities
- CompanyPluri Inc.
US‑listed biotech company entering the partnership.
- CompanyZEO ScientifiX, Inc.
Partner receiving licensing rights and issuing equity to Pluri.
- InvestorGreyt Ventures LLC
Controlling stockholder of ZEO involved in share exchanges.
- IndividualIan Bothwell
Controlling shareholder of ZEO participating in share swaps.
- IndividualDr. George Shapiro
ZEO’s Chief Medical Officer involved in share exchange.



